Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Pharmacogenomics|July 18, 2013
OCT1 genetic variants influence the pharmacokinetics of morphine in childrenTsuyoshi Fukuda, Vidya Chidambaran, Tomoyuki Mizuno, et al.
Transplantation|April 12, 2012
Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantationDavid K Hooper, Tsuyoshi Fukuda, Rhonda Gardiner, et al.
Journal of Opioid Management|September 4, 2012
Morphine clearance in children: does race or genetics matter?Senthilkumar Sadhasivam, Elke H J Krekels, Vidya Chidambaran, et al.
Rinsho Byori. the Japanese Journal of Clinical Pathology|April 20, 2007
Determination of single nucleotide polymorphisms in N-acetyltransferase2 gene using an electrochemical DNA chip and an automated DNA detection systemNaoko Nakamura, Keiko Ito, Sadato Hongo, et al.
Journal of Clinical Psychopharmacology|September 17, 2008
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipranMasataka Wakeno, Masaki Kato, Gaku Okugawa, et al.
The Journal of Antimicrobial Chemotherapy|September 3, 2016
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysisKevin J Downes, Min Dong, Tsuyoshi Fukuda, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|May 17, 2008
Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorderMasaki Kato, Tsuyoshi Fukuda, Masataka Wakeno, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 5, 2007
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorderMasaki Kato, Tsuyoshi Fukuda, Alessandro Serretti, et al.
Pageof 14